On December 26th 2023, AbbVie announced that it will acquire Massachusetts based biotech Cerevel Therapeutics for $45.00 per share. The transaction represents an equity value
AbbVie has agreed to acquire cancer biotech ImmunoGen (IMGN) for $10.1 billion in an all cash offering for $31.26 per share. J.P Morgan and Morgan
Suppose you were teleported to Copenhagen, Denmark this instant. A look around would yield a scene far different from what we are accustomed to in
For an estimated 6.7 million Americans, the days are the same. Memory loss, poor judgment, difficulty completing simple tasks, and getting lost are a few
In what has been a down year for mergers and acquisitions deals, Amgen made headlines late last year by announcing it will acquire Horizon for
As the recent rise of pre-clinical initial public offerings (IPOs) indicates, investors in the life sciences no longer need to see an actual treatment to
So you are worried about your pipeline? That’s totally valid. 90% of clinical drug candidates fail in clinical trials. Compounding the problem, drug development is
In the life science industry, product development has evolved into a costly endeavor. Translational tools seek to change this. Despite the promise of a novel